SKIP TO CONTENT
30+/SKIN
← FORMULARYRECORD 30S-TR-05FORMAT TREATMENT
NO. 05
0530 ML
PACKAGINGALUMINIUM TUBE
FILL30 ML
DOSES≈ 85
COST / DOSE£0.68
PRICE£58

SPECIMEN CATALOGUE — NO ORDER WILL BE PLACED

TREATMENT / AM/PM

AZELAIC 10%

Redness, pigment and lesions, one vector each.

ACTIVE LOAD18.0%
WORKING pH4.6 ± 0.2
VISCOSITY4,800 cP
FINISHMatte
FORMULATION
BASESuspension in silicone-free emollient
TEXTUREGrainy on contact, dissolves in 5 s
STABILITY12 MONTHS FROM OPENING
PEAK IRRITATION2 / 10
SCHEDULE
PHASEAM/PM
STEP ORDER03
FREQUENCYDAILY
DOSEPEA-SIZED
01

Composition

% W/W AT COMPOUNDING
  • Azelaic Acid

    Treats redness, post-inflammatory pigment and breakouts at once. Almost nothing else does all three.

    ACTS AT EPIDERMISONSET 6–10 WKIRRITATION 2/10
    CONC.10%
    56% OF ACTIVE LOAD
  • Tranexamic Acid

    The pigment active that works on the vascular component — the one that survives sun exposure.

    ACTS AT EPIDERMISONSET 8–12 WKIRRITATION 1/10
    CONC.3%
    17% OF ACTIVE LOAD
  • Niacinamide

    The generalist. Barrier, tone, oil and pore visibility all move a little. Nothing moves a lot.

    ACTS AT EPIDERMISONSET 4–8 WKIRRITATION 1/10
    CONC.5%
    28% OF ACTIVE LOAD
FULL INCI, DESCENDING
  1. 01Aqua
  2. 02Azelaic Acid
  3. 03Niacinamide
  4. 04Tranexamic Acid
  5. 05Squalane
  6. 06Glycerin
  7. 07Panthenol
  8. 08Xanthan Gum
EXCLUDED BY POLICY
  • FRAGRANCE
  • DENAT. ALCOHOL
  • ESSENTIAL OILS
  • COLOURANT
02

Measured endpoints

MEDIAN CHANGE VS. VEHICLE
Inflammatory lesion count-41%
12 WKREF-05
Erythema index-22%
12 WKREF-08
Melanin index (MASI)-24%
16 WKREF-04
SUPPORTING RECORDS
  • Randomised, active-controlled

    N=96 · 16 WK · DOUBLE-BLIND

  • Split-face, vehicle-controlled

    N=72 · 12 WK · INVESTIGATOR-BLIND

  • Randomised, vehicle-controlled

    N=88 · 12 WK · DOUBLE-BLIND

  • In vitro enzymatic assay

    N=12 · N/A · N/A

RECORDS ARE ILLUSTRATIVE PLACEHOLDERS AUTHORED FOR THIS SPECIMEN CATALOGUE. THEY CITE NO REAL STUDY, AUTHOR OR JOURNAL.
DEPTH 000%SEC